By Connor HartShares of vTv Therapeutics tumbled after the Food and Drug Administration placed a clinical hold on the company's program studying a treatment for Type 1 diabetes. Shares ended the market trading session up 1% at $21.20, putting them up more than 84% since the beginning of the year. Cadisegliatin is a novel, oral, small-molecule, liver-selective glucokinase activator with first-in-class potential as an adjunct treatment for Type 1 diabetes, the company said. "We are working diligently with the Agency to resolve the clinical hold and resume enrollment as quickly as possible," Chief Executive Paul Sekhri said. Write to Connor Hart at connor.hart@wsj.com(END) Dow Jones NewswiresJuly 26, 2024 18:06 ET (22:06 GMT)Copyright (c) 2024 Dow Jones & Company, Inc.

Source: Wall Street Journal July 27, 2024 10:13 UTC